AAAAAA

   
Results: 1-25 | 26-48
Results: 1-25/48
Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer
Authors: Kakolyris, S Giatromanolaki, A Koukourakis, M Powis, G Souglakos, J Sivridis, E Georgoulias, V Gatter, KC Harris, AL
Citation: S. Kakolyris et al., Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer, CLIN CANC R, 7(10), 2001, pp. 3087-3091
First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study
Authors: Papakostas, P Kouroussis, C Androulakis, N Samelis, G Aravantinos, G Kalbakis, K Sarra, E Souglakos, J Kakolyris, S Georgoulias, V
Citation: P. Papakostas et al., First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study, EUR J CANC, 37(15), 2001, pp. 1833-1838
Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: A multicenter phase II study
Authors: Alexopoulos, A Kouroussis, C Malamos, N Kakolyris, S Kalbakis, K Kosmas, C Mavroudis, D Agelaki, S Vlachonicolis, J Sarra, E Rigatos, G Georgoulias, V
Citation: A. Alexopoulos et al., Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: A multicenter phase II study, ANN ONCOL, 12(6), 2001, pp. 793-798
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer
Authors: Mavroudis, D Papadakis, E Veslemes, M Tsiafaki, X Stavrakakis, J Kouroussis, C Kakolyris, S Bania, E Jordanoglou, J Agelidou, M Vlachonicolis, J Georgoulias, V
Citation: D. Mavroudis et al., A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer, ANN ONCOL, 12(4), 2001, pp. 463-470
Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): A multicenter phase II study
Authors: Kakolyris, S Mavroudis, D Tsavaris, N Souglakos, J Tsiafaki, P Kalbakis, K Agelaki, S Androulakis, N Georgoulias, V
Citation: S. Kakolyris et al., Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): A multicenter phase II study, ANN ONCOL, 12(2), 2001, pp. 193-197
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer
Authors: Stathopoulos, GP Mavroudis, D Tsavaris, N Kouroussis, C Aravantinos, G Agelaki, S Kakolyris, S Rigatos, SK Karabekios, S Georgoulias, V
Citation: Gp. Stathopoulos et al., Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer, ANN ONCOL, 12(1), 2001, pp. 101-103
Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/REF-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome
Authors: Koukourakis, MI Giatromanolaki, A Kakolyris, S Sivridis, E Georgoulias, V Funtzilas, G Hickson, ID Gatter, KC Harris, AL
Citation: Mi. Koukourakis et al., Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/REF-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome, INT J RAD O, 50(1), 2001, pp. 27-36
A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors
Authors: Kouroussis, C Kakolyris, S Mavroudis, D Androulakis, N Kalbakis, K Agelaki, S Sarra, E Souglakos, J Christodoulakis, M Samonis, G Georgoulias, V
Citation: C. Kouroussis et al., A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors, AM J CL ONC, 24(4), 2001, pp. 404-407
A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer
Authors: Agelaki, S Kakolyris, S Palamidas, P Kouroussis, C Mavroudis, D Kalbakis, K Georgoulias, V Raptis, A
Citation: S. Agelaki et al., A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer, LUNG CANC, 34(1), 2001, pp. 133-139
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study
Authors: Kakolyris, S Papadakis, E Tsiafaki, X Kalofonos, C Rapti, A Toubis, M Bania, E Kouroussis, C Chainis, K Androulakis, N Agelaki, S Sarra, E Vardakis, N Georgoulias, V
Citation: S. Kakolyris et al., Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study, LUNG CANC, 32(2), 2001, pp. 179-187
A phase I clinical trial of topotecan given every 2 weeks in patients withrefractory solid tumors
Authors: Kakolyris, S Kouroussis, C Souglakos, J Mavroudis, D Agelaki, S Kalbakis, K Androulakis, N Vardakis, N Vamvakas, L Georgoulias, V
Citation: S. Kakolyris et al., A phase I clinical trial of topotecan given every 2 weeks in patients withrefractory solid tumors, ONCOL-BASEL, 61(4), 2001, pp. 265-270
Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: A phase II study
Authors: Kouroussis, C Souglakos, J Kakolyris, S Mavroudis, D Malamos, N Kalbakis, K Androulakis, N Agelaki, A Vardakis, N Samonis, G Georgoulias, V
Citation: C. Kouroussis et al., Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: A phase II study, ONCOL-BASEL, 61(1), 2001, pp. 36-41
A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer
Authors: Kakolyris, S Souglakos, J Kouroussis, C Androulakis, N Mavroudis, D Kalbakis, K Kotsakis, A Vardakis, N Koukourakis, M Romanos, J Georgoulias, V
Citation: S. Kakolyris et al., A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer, ONCOL-BASEL, 60(3), 2001, pp. 207-213
Plasminogen activator inhibitor-I as a measure of vascular remodelling in breast cancer
Authors: Fox, SB Taylor, M Grondahl-Hansen, J Kakolyris, S Gatter, KC Harris, AL
Citation: Sb. Fox et al., Plasminogen activator inhibitor-I as a measure of vascular remodelling in breast cancer, J PATHOLOGY, 195(2), 2001, pp. 236-243
Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuousinfusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes
Authors: Kalbakis, K Kouroussis, C Kakolyris, S Mavroudis, D Souglakos, J Agelaki, S Vamvakas, L Christodoulakis, M Stylianou, K Georgoulias, V
Citation: K. Kalbakis et al., Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuousinfusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes, BR J CANC, 85(6), 2001, pp. 798-802
c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer
Authors: Koukourakis, MI Giatromanolaki, A Guddo, F Kaklamanis, L Vignola, M Kakolyris, S Turley, H Georgoulias, V Bonsignore, G Gatter, KC Harris, AL
Citation: Mi. Koukourakis et al., c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer, J IMMUNOTH, 23(1), 2000, pp. 104-114
Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer
Authors: Koukourakis, MI Giatromanolaki, A Kakolyris, S Froudarakis, M Georgoulias, V Retalis, G Bahlitzanakis, N
Citation: Mi. Koukourakis et al., Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer, MED ONCOL, 17(2), 2000, pp. 135-143
Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer
Authors: Giatromanolaki, A Koukourakis, MI Stathopoulos, GP Kapsoritakis, A Paspatis, G Kakolyris, S Sivridis, E Georgoulias, V Harris, AL Gatter, KC
Citation: A. Giatromanolaki et al., Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer, ONCOL RES, 12(1), 2000, pp. 33-41
Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study
Authors: Giannakakis, T Ziras, N Kakolyris, S Mavroudis, D Androulakis, N Agelaki, S Parashos, M Sarra, E Dimou, T Hatzidaki, D Vlachonikolis, J Georgoulias, V
Citation: T. Giannakakis et al., Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study, EUR J CANC, 36(6), 2000, pp. 742-747
Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin
Authors: Kakolyris, S Kouroussis, C Kalbakis, K Mavroudis, D Souglakos, J Vardakis, N Kremos, S Georgoulias, V
Citation: S. Kakolyris et al., Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin, ANN ONCOL, 11(6), 2000, pp. 757-760
Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study
Authors: Mavroudis, D Alexopoulos, A Ziras, N Malamos, N Kouroussis, C Kakolyris, S Agelaki, S Kalbakis, K Tsavaris, N Potamianou, A Rigatos, G Georgoulias, V
Citation: D. Mavroudis et al., Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study, ANN ONCOL, 11(10), 2000, pp. 1249-1254
Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study
Authors: Koukourakis, MI Kyrias, G Kakolyris, S Kouroussis, C Frangiadaki, C Giatromanolaki, A Retalis, G Georgoulias, V
Citation: Mi. Koukourakis et al., Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study, J CL ONCOL, 18(11), 2000, pp. 2226-2233
A dose escalation study of weekly docetaxel in patients with advanced solid tumors
Authors: Kouroussis, C Agelaki, S Mavroudis, D Souglakos, J Kakolyris, S Kalbakis, K Vardakis, N Reppa, D Hatzidaki, D Samonis, G Georgoulias, V
Citation: C. Kouroussis et al., A dose escalation study of weekly docetaxel in patients with advanced solid tumors, CANC CHEMOT, 46(6), 2000, pp. 488-492
High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas - Rationale for combination with radiotherapy
Authors: Koukourakis, MI Koukouraki, S Giatromanolaki, A Kakolyris, S Georgoulias, V Velidaki, A Archimandritis, S Karkavitsas, NN
Citation: Mi. Koukourakis et al., High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas - Rationale for combination with radiotherapy, ACTA ONCOL, 39(2), 2000, pp. 207-211
Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF) - A phase II trial
Authors: Mavroudis, D Kourousis, C Androulakis, N Kalbakis, K Agelaki, S Kakolyris, S Souglakos, J Sarra, E Vardakis, N Hatzidaki, D Sarmonis, G Georgoulias, V
Citation: D. Mavroudis et al., Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF) - A phase II trial, AM J CL ONC, 23(4), 2000, pp. 341-344
Risultati: 1-25 | 26-48